Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Amortization of Deferred Charges (2017 - 2023)

Neurocrine Biosciences filings provide 7 years of Amortization of Deferred Charges readings, the most recent being $100000.0 for Q4 2023.

  • On a quarterly basis, Amortization of Deferred Charges fell 50.0% to $100000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was $700000.0, a 41.67% decrease, with the full-year FY2023 number at $700000.0, down 41.67% from a year prior.
  • Amortization of Deferred Charges hit $100000.0 in Q4 2023 for Neurocrine Biosciences, down from $200000.0 in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $400000.0 in Q2 2019 to a low of $100000.0 in Q4 2023.
  • Median Amortization of Deferred Charges over the past 5 years was $300000.0 (2019), compared with a mean of $290000.0.
  • Biggest five-year swings in Amortization of Deferred Charges: soared 33.33% in 2022 and later crashed 50.0% in 2023.
  • Neurocrine Biosciences' Amortization of Deferred Charges stood at $400000.0 in 2019, then changed by 0.0% to $400000.0 in 2020, then fell by 25.0% to $300000.0 in 2021, then tumbled by 33.33% to $200000.0 in 2022, then crashed by 50.0% to $100000.0 in 2023.
  • The last three reported values for Amortization of Deferred Charges were $100000.0 (Q4 2023), $200000.0 (Q3 2023), and $200000.0 (Q2 2023) per Business Quant data.